KUMAR RAVINDRA,GRINBERG ASYA,SAKO DIANNE S,PEARSALL ROBERT SCOTT,CASTONGUAY ROSELYNE
申请号：
IN201717038988
公开号：
IN201717038988A
申请日:
2017.11.01
申请国别(地区):
IN
年份:
2017
代理人:
摘要：
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular do -main of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threoninekinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising anextracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments,the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALKl,ALK.2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such solublepolypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone,cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolicparameters, and disorders associated with these tissues, cellular networks, and endocrine systems.
